61324-89-8 Usage
Uses
Used in Pharmaceutical Synthesis:
Benzene, 4-(difluoromethyl)-1-fluoro-2-nitroserves as a key intermediate in the production of pharmaceuticals. Its unique structure allows for the development of new drugs with specific therapeutic properties, contributing to advancements in medicine.
Used in Agrochemical Production:
Benzene, 4-(difluoromethyl)-1-fluoro-2-nitrois also utilized in the synthesis of agrochemicals, playing a crucial role in the creation of pesticides and other agricultural products designed to protect crops and enhance yields.
Used in Organic Chemistry Research:
Due to its reactive functional groups, Benzene, 4-(difluoromethyl)-1-fluoro-2-nitrois a valuable compound in organic chemistry research. It can be used to explore new reaction pathways and develop innovative synthetic methods for complex organic molecules.
Toxicological Studies:
The mutagenic potential of Benzene, 4-(difluoromethyl)-1-fluoro-2-nitrohas been a subject of interest in toxicological studies. Understanding its effects on genetic material can help in assessing its safety and developing guidelines for its use in various applications.
Safety and Handling:
Given its potential hazards, proper handling and storage of Benzene, 4-(difluoromethyl)-1-fluoro-2-nitroare essential to ensure safety in laboratory and industrial settings. This includes adhering to safety protocols and using appropriate protective equipment when working with Benzene, 4-(difluoromethyl)-1-fluoro-2-nitro-.
Check Digit Verification of cas no
The CAS Registry Mumber 61324-89-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,1,3,2 and 4 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 61324-89:
(7*6)+(6*1)+(5*3)+(4*2)+(3*4)+(2*8)+(1*9)=108
108 % 10 = 8
So 61324-89-8 is a valid CAS Registry Number.
61324-89-8Relevant academic research and scientific papers
MAXI-K POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF FRAGILE X ASSOCIATED DISORDERS
-
Page/Page column 100-101, (2021/11/26)
The present invention relates to the compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as maxi-K potassium channel openers, which makes them suitable for use in therapy, particularly in the treatment or prevention of fragile X associated disorders, such as fragile X syndrome.
KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER
-
Paragraph 00172, (2018/03/09)
The present invention relates to a compound having the structure of formula (I) or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where X, Y, Z, R, R1, R2, R3, R4, R5, and R6 are as described herein. The present invention also relates to compositions containing the compound having the structure of formula (I), and a method of treating cancer in a subject.
Tricyclic Compounds As mPGES-1 Inhibitors
-
Page/Page column 36, (2012/05/07)
The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.
Thieno[3,2-b]-[1,5]benzodiazepines
-
, (2008/06/13)
Thieno[1,5]benzodiazepines having useful CNS activity containing the novel tricyclic ring system: STR1 the 10-position being substituted by an amino, preferably a piperazino, group.
